Cetuximab ELISA Kit (ab237648)
Key features and details
- Sensitivity: 100 ng/ml
- Range: 100 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Cetuximab ELISA Kit
See all Cetuximab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15% -
Sample type
Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
100 ng/ml -
Range
100 ng/ml - 3000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Note: Cetuximab ELISA kit ab237648 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Cetuximab in the sample or standard. Results of samples can be determined directly using the standard curve.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4379 BioSim™ Cetuximab (Human) ELISA Kit. E4379-100 is the same size as the 96 test size of ab237648.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests 96 tests Assay Buffer 2 x 50ml 2 x 50ml Cetuximab Standard S1 1 x 0.3ml 1 x 0.3ml Cetuximab Standard S2 1 x 0.3ml 1 x 0.3ml Cetuximab Standard S3 1 x 0.3ml 1 x 0.3ml Cetuximab Standard S4 1 x 0.3ml 1 x 0.3ml Cetuximab Standard S5 1 x 0.3ml 1 x 0.3ml Cetuximab Standard S6 1 x 0.3ml 1 x 0.3ml Cetuximab Standard S7 1 x 0.3ml 1 x 0.3ml HRP-conjugate Probe 1 x 12ml 1 x 12ml Micro ELISA Plate 1 unit 1 unit Plate sealers 2 units 2 units Stop Solution 1 x 12ml 1 x 12ml TMB substrate 1 x 12ml 1 x 12ml Wash buffer (20X) 1 x 50ml 1 x 50ml -
Relevance
Cetuximab is a chimeric monoclonal antibody of the immunoglobulin G1 (IgG1) and FDA-approved epidermal growth factor receptor (EGFR) inhibitor. Preclinical studies have shown that cetuximab enhances the antitumour effects of chemotherapy as well as radiotherapy by inhibiting cell proliferation, angiogenesis and metastasis and by promoting apoptosis is used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab blocks growth factor-induced activation of the downstream mitogen-activated protein kinase, inhibiting cell proliferation. It also decreases angiogenic factors, inhibits tumor-cell invasion and metastasis via downregulation of matrix metalloproteinases (MMPs) and VEGF, and promotes apoptosis by upregulating apoptotic protein, Bax, with the help of other chemotherapeutic agents. -
Alternative names
- Erbitux
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab237648 has not yet been referenced specifically in any publications.